FDA is warning about testosterone-boosting drugs


This happen when sales of testosterone drugs exceeded $2 billion. “We don’t know very much about this therapy,” Dr. Steve Nissen, a cardiologist at the Cleveland Clinic told to the media. The consumer advocacy group petitioned the FDA last February to add a boxed warning to testosterone drugs about heart risks. It was not applied. Drugs like AbbVie’s Androgel and Lilly’s Axiron are at the top of sales. Actually, such drugs are sold in a  variety of forms, even as gels or deodorants. AbbVie said in a statement that the company “is committed to our patients and we continue to work with the FDA.” The FDA began reviewing the safety of testosterone drugs in January 2014.


Please enter your comment!
Please enter your name here